Cluster-market location and tenant credit drive the best executions.
Who buys life sciences & lab?
Life sciences sponsors concentrate around the established cluster markets. Boston/Cambridge, San Francisco/South SF, San Diego, Research Triangle (NC), Seattle, the New York/New Jersey corridor, and selectively Philadelphia, Maryland, and Houston. The largest publicly traded life-sciences REITs and a handful of large privates own most of the institutional inventory in those clusters. Mid-market and emerging-cluster sponsors run smaller portfolios on bank or debt-fund debt.
The asset class went through a meaningful supply correction in 2023 to 2024 as biotech venture capital and IPO activity slowed and several speculative lab projects came online into a softer demand environment. Per industry cluster reports, vacancy in the major clusters has stabilized but remains higher than the cycle low, and lender appetite has narrowed to the strongest sub-clusters and tenant credits. Sponsors with established cluster relationships and proven build-out track records have a meaningful financing edge.
Which capital sources finance life sciences & lab?
Five capital pools fund Life Sciences & Lab in 2026. Each one has a different appetite, leverage band, and execution speed. The cross-links below go to the full lender taxonomy for each category.
What do typical Life Sciences & Lab loan terms look like?
The table below summarizes 2026 indicative terms by capital source. Real quotes vary by sponsor profile, basis, lease credit, and submarket. Send the deal for a current quote.
2026 life sciences pricing benchmarks. Indicative ranges only, send the deal for a current quote.
| Capital source | LTV / LTC | DSCR / debt yield | Term / amort | Recourse |
|---|
Why is life sciences a separate underwriting bucket from office?
Three structural differences. First, build-out cost, fully fitted-out wet lab runs $200 to $400+ PSF in 2026 vs. $80 to $150 PSF for high-end medical office or $40 to $80 PSF for premium general office. Second, tenant base, biotech, biopharma, and academic research tenants have different credit profiles, lease structures, and space requirements than general office tenants. Third, infrastructure, vibration isolation, dedicated exhaust, redundant power, gas piping, and HVAC tonnage are real-estate-specific requirements that drive both upfront cost and ongoing operating complexity.
The result is a separate cap-rate stack, a separate lender options, and a separate set of underwriting questions. Per industry research, life-sciences cap rates and pricing trade in their own band depending on cluster market and tenant quality. Lenders who underwrite life sciences well treat it as its own asset class, not as a flavor of office.
How do lenders underwrite a life sciences deal?
Three drivers: cluster-market location, tenant credit, and build-out spec. Lenders separate the universe by cluster, top-cluster Boston/Cambridge and South SF deals get tighter sizing and more aggressive terms; emerging-cluster deals get more conservative underwriting. Cap rates on stabilized institutional cluster-market lab range 5.50% to 7.00% in 2026; emerging clusters and value-add trade 100 to 200 bps wide.
Tenant underwriting includes cash runway analysis (for pre-revenue biotech), parent-guaranty review, lease-guaranty stack, and milestone risk for clinical-trial-driven tenants. Lenders solve to debt yield (typically 8.5% to 10% on stabilized) and DSCR (1.30x), and require TI/LC reserves sized to expected mid-loan rollover.
What does a typical life sciences construction term sheet look like?
Recourse: completion guaranty from the sponsor parent or a creditworthy affiliate, typically burning off at substantial completion. Lease-up guaranty on speculative lab capacity. The exit takeout to CTL perm or stabilized CMBS is built into the credit memo from quote; the perm market needs to support the proforma sizing 36 to 48 months out, with credible cluster-market comps for both rent and cap rate.
How do lenders treat office-to-lab conversion?
Office-to-lab conversion gained traction in 2021 to 2023 as office vacancy rose and lab demand seemed to be growing without limit. The 2024 supply correction recalibrated expectations, conversions are still happening, but lenders now require credible cluster-market location, signed pre-leases (or strong leasing pipeline), and contingency reserves sized to TI overruns and longer-than-planned timelines.
Conversion cost runs $150 to $300 PSF in 2026 depending on existing-building infrastructure, ceiling heights, slab-to-slab, and floor loading. Buildings with 14'+ slab-to-slab, strong column grids, and existing risers convert most efficiently; older office stock with low ceilings and tight columns may not be economical to convert. Lenders require detailed engineering and cost estimates before quote.
When is CTL perm the right execution?
The trade-off for the cheapest pricing is non-recourse leverage capped at lease-driven sizing and a slow, conservative process (75 to 120 days from term sheet to closing). Sponsors who want maximum leverage on the same property would route to CMBS or to a higher-leverage debt-fund execution; sponsors who want long-term hold and the cheapest cost of capital default to CTL.
Financing options for life sciences & lab
Each capital path below has a dedicated page covering leverage, pricing, the active lender options, deal-size sweet spot, recourse posture, and take-out for life sciences & lab.
What can delay the financing?
These are the items that, in practice, hold up or re-trade closings on this niche. Front-load each one in due diligence.
- Cluster-market location. Lender appetite is heavily concentrated in Boston/Cambridge, South SF, San Diego, Research Triangle, and Seattle. Emerging clusters get tighter sizing, more bridge execution, and shorter fixed-rate terms.
- Tenant credit and runway. Pre-revenue biotech tenants are underwritten on cash runway, IP value, and clinical-trial milestones rather than current EBITDA. Lenders apply runway haircuts and may require letters of credit, security deposits, or parent guaranties.
- Build-out spec and percentage of wet lab. Spec lab build-out costs $200 to $400+ PSF in 2026; lenders look at the percentage of wet-lab area, ventilation tonnage, and exhaust spec. Office-to-lab conversion costs typically run 30% to 40% of new-construction lab on a TI basis.
- Re-tenanting cost. The same specialized build-out that wins the original tenant is expensive to demolish and re-spec for a different tenant. Lenders size TI/LC reserves to expected mid-loan rollover.
- Vivarium and biosafety containment. Vivarium space (animal facilities) and BSL-2/3 containment add cost and operating complexity. Lenders need engineering reports confirming the build-out and the operating permits.
Frequently asked questions
What's the typical leverage on life sciences construction?
60% to 75% loan-to-cost depending on tenant credit, pre-leasing, and execution type.
How much does fitted-out wet lab cost to build?
$200 to $400+ PSF in 2026 for new-construction wet lab in cluster markets, depending on percentage of wet-lab vs. office, ventilation tonnage, redundant systems, and biosafety containment level. Office-to-lab conversion runs $150 to $300 PSF depending on existing-building infrastructure.
Which markets do life sciences lenders actually like?
Boston/Cambridge, San Francisco/South SF, San Diego, Research Triangle (NC), and Seattle anchor the institutional bench. Selective lender appetite in Philadelphia, Maryland, and Houston. Emerging clusters get smaller checks, tighter sizing, and shorter fixed-rate terms.
How do lenders underwrite pre-revenue biotech tenants?
Cash runway analysis (months of operating expense covered by cash on balance sheet), IP value, clinical-trial milestone risk, and parent-or-affiliate guaranty stack. Lenders apply runway haircuts and may require letters of credit, security deposits, or parent guaranties from larger affiliates.
What's a credit-tenant lease (CTL) execution?
A perm financing structure where the lender underwrites primarily on the credit of a single investment-grade tenant under a long-term triple-net or modified-gross lease. Common in life sciences for buildings leased to large biotech, pharma, or academic medical centers. Life cos lead the CTL market.
Did life sciences cap rates reset after 2024?
Yes. Per industry cluster transaction data, life-sciences cap rates widened by 50 to 125 bps in cluster markets and meaningfully more in emerging clusters during the 2023 to 2024 supply correction. Cap rates have stabilized at the new range, and lender appetite has narrowed to the strongest sub-clusters and tenant credits.
Are office-to-lab conversions still being financed?
Selectively. Lenders require credible cluster-market location, signed pre-leases or a strong leasing pipeline, and contingency reserves sized to TI overruns and longer timelines. Buildings with 14'+ slab-to-slab, strong columns, and existing risers convert most efficiently; older office stock may not be economical.
Sources
- Capital Markets Special Report: Insurance Industry CRE Mortgage Holdings · National Association of Insurance Commissioners (NAIC) · 2025-Q4
- Senior Loan Officer Opinion Survey on Bank Lending Practices (SLOOS) · Board of Governors of the Federal Reserve System · 2026-Q1
- Quarterly Banking Profile · Federal Deposit Insurance Corporation · 2026-Q1
- NAIOP Research Foundation: Industrial Space Demand Forecast · NAIOP Research Foundation · 2026-Q1